Hit by FDA red flags, cit­ed for mis­lead­ing in­vestors and bat­tered by a thumbs-down from ex­perts, it’s been one ter­ri­ble week for Treve­na

Treve­na’s fall from grace — and in­to pen­ny stock ter­ri­to­ry — gath­ered steam on Thurs­day evening as a slight ma­jor­i­ty of out­side ex­perts at the FDA turned thumbs down on their pain med and lawyers be­gan to pitch a class ac­tion suit claim­ing the com­pa­ny had ac­tive­ly mis­led in­vestors for 2 years about the biotech’s dis­cus­sions with reg­u­la­tors.

Al­ready down sharply af­ter the in-house re­view pro­vid­ed a scathing as­sess­ment of mixed ef­fi­ca­cy and safe­ty da­ta, the 8-7 vote against an ap­proval car­ried fresh penal­ties as Treve­na’s stock $TRVN slid down to 71 cents a share in af­ter-mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER